SCHEMBL24232129

SCHEMBL24232129

COc1cc2ncc(-c3cccc(N[C@H]4CNC[C@@H]4F)n3)n2cc1[C@](C)(O)C(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 17/20 0.54
NRAS P01111 12/20 0.54
IRAK4 Q9NWZ3 5/20 0.49
IRAK1 P51617 3/20 0.49
PDGFRB P09619 2/20 0.49
CDK7 P50613 2/20 0.49
CCNH P51946 2/20 0.49
LCK P06239 1/20 0.49
RET P07949 1/20 0.49
CHEK2 O96017 1/20 0.48
ABL1 P00519 1/20 0.48
PDGFRA P16234 1/20 0.48
FLT4 P35916 1/20 0.48
KDR P35968 1/20 0.48
DDR1 Q08345 1/20 0.48
NTRK3 Q16288 1/20 0.48
AURKB Q96GD4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25990612 1.00 FLT3 (0.54) FLT3NRASIRAK4IRAK1PDGFRB
SCHEMBL29370146 1.00 FLT3 (0.54) FLT3NRASIRAK4IRAK1PDGFRB
SCHEMBL25990613 1.00 FLT3 (0.54) FLT3NRASIRAK4IRAK1PDGFRB
SCHEMBL24231370 1.00 FLT3 (0.54) FLT3NRASIRAK4IRAK1PDGFRB
SCHEMBL24231377 0.93 FLT3 (0.60) FLT3NRASIRAK4IRAK1PDGFRB
SCHEMBL24231682 0.93 FLT3 (0.60) FLT3NRASIRAK4IRAK1PDGFRB
SCHEMBL30621236 0.93 FLT3 (0.60) FLT3NRASIRAK4IRAK1PDGFRB
SCHEMBL25991241 0.93 FLT3 (0.60) FLT3NRASIRAK4IRAK1PDGFRB
SCHEMBL30621260 0.93 FLT3 (0.56) FLT3NRASIRAK4IRAK1PDGFRB
SCHEMBL24231314 0.93 FLT3 (0.56) FLT3NRASIRAK4IRAK1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303563-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER 2023-09-28 US disclosed
WO-2023150601-A2 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-08-10 WO disclosed
WO-2022026935-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2022-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303563-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF FLT3, IRAK2, IRAK3 FLT3 1/4885NRAS 259/4885IRAK4 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.